NICE calls for more info on Opdivo for Hodgkin lymphoma
The National Institute for Health and Clinical Excellence (NICE) has today published new draft guidance recommending that Bristol-Myers Squibb (NYSE: BMY), which manufactures Opdivo (nivolumab), provides more information on its drug's effectiveness for treating classical Hodgkin lymphoma.
The independent appraisal committee of the cost-effectiveness watchdog for England and Wales, recognized that nivolumab is an innovative and promising treatment, but concluded that the evidence presented was highly uncertain due to immature data and did not reflect how the drug would be used in UK clinical practice.
The NICE requests that the company provides a revised analysis on the drug’s cost-effectiveness that takes into account the committee’s concerns at the next appraisal meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze